Just as importantly, the addition of extra ingredients creates a formulation that differs from the branded products, which compounders may use as a legal justification to avoid producing an outright copy of a brand-name drug.Recall Initiation Date: July 18, 2025Link: FDA Enforcement Report Semaglutide Company: Boothwyn Pharmacy, LLC (licensed compounding pharmacy)Location: Kennett Square, PennsylvaniaScope: Semaglutide, 2.5 mg/mL injection: .8 mL (186 vials), 2 mL (642 vials), 4 mL (648 vials)Drug Description: Treats type 2 diabetes and obesityRecall Reason: Subpotent drugs (which means they less than the specified amount of active ingredient)Recall Initiation Date: July 9, 2025Link: FDA Enforcement Report Semaglutide, Semaglutide/Cyanocobalamin, Tirzepatide, Tirzepatide/Cyanocobalamin Company: Thrive Health and Wellness, LLC, dba Thrive Health Solutions (Colorado)Location: Englewood, ColoradoScope: Semaglutide: 5 mg/mL (164 pre-filled syringes)
These results align with prior studies, such as the BARI-OPTIMISE trial [28], which reported a 9.4 kg weight loss with liraglutide in a similar population
Yu J, Zhang Y, Ye Y, DiSanto R, Sun W, Ranson D, et al
Each pen holds 4 maintenance doses of either 0.5 mg, 1 mg, or 2 mg of medicine given once weekly and will last for one month
For Zepbound (weight management indication), doses increase from 2.5 mg to 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg at 4-week intervals as tolerated
Medicare and commercial payers continue to scrutinize injection claims in 2026, making accurate documentation more important than ever
.jpg?v=1749039868)
